Back to results
US 2011/0256098 A1Published application
Immunotherapy for chronic hepatitis c virus infection
AssigneeGlobeImmune, Inc.
InventorsDavid Apelian, Richard C. Duke, Alex Franzusoff
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeGlobeImmune, Inc.
InventorsDavid Apelian, Richard C. Duke, Alex Franzusoff
Estimating the term…
Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and/or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.
A method to treat chronic hepatitis C virus (HCV) infection, comprising administering to a subject an immunotherapeutic composition comprising a yeast vehicle expressing at least one HCV antigen or immunogenic domain thereof, and further administering to the subject one or both of at least one interferon and at least one anti-viral compound;
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method to increase the frequency of rapid virologic responses (RVR) and/or early virologic responses (EVR/cEVR) in a population of subjects chronically infected with hepatitis C virus (HCV), as compared to RVR and EVR/cEVR in a population of subjects chronically infected with HCV and treated only with combination interferon and anti-viral therapy, the method comprising administering to the population of subjects an immunotherapeutic composition comprising a yeast vehicle expressing at least one HCV antigen or immunogenic domain thereof that elicits a T cell-mediated immune response against one or more HCV antigens in combination with interferon and an anti-viral compound.
(canceled)
(canceled)
(canceled)
(canceled)
A method to increase the number of complete responders in a population of subjects chronically infected with hepatitis C virus (HCV), as compared to the number of complete responders in a population of subjects chronically infected with HCV that is treated only with interferon and anti-viral therapy, the method comprising administering to the population of subjects an immunotherapeutic composition comprising a yeast vehicle expressing at least one HCV antigen or immunogenic domain thereof that elicits a T cell-mediated immune response against one or more HCV antigens in combination with interferon and an anti-viral compound.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method to treat a subject who is chronically infected with HCV, comprising:
A method to continue treatment of a chronically HCV-infected subject who is predicted to fail combination interferon-anti-viral compound therapy, comprising administering to the subject an immunotherapeutic composition comprising a yeast vehicle expressing at least one HCV antigen or immunogenic domain thereof that elicits a T cell-mediated immune response against one or more HCV antigens.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
74-135. (canceled)
Dependencies are inferred from the claim text.